SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-Effectiveness of MODY Genetic Testing: Translating Genomic Advances Into Practical Health Applications
3 references·1 citing·19 second hop
Cost-Effectiveness of MODY Genetic Testing: Translating Genomic Advances Into Practical Health Applications (2013)Cost-Effectiveness of MODY Genetic Testin…What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)What Does the Value of Modern…A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) (2004)A model to estimate the lifet…Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel …Cost-effectiveness of precision medicine: a scoping review (2019)Cost-effectiveness of precisi…EuroQol - a new facility for the measurement of health-related quality of life (1990)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)Recommendations for Reporting Cost-effectiveness Analyses (1996)Variations in population health status: results from a United Kingdom national questionnaire survey (1998)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)Economic Consequences of Diabetes Mellitus in the U.S. in 1997 (1998)Projecting the Future Diabetes Population Size and Related Costs for the U.S. (2009)State-Transition Modeling (2012)State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 (2012)Free for All? Lessons from the RAND Health Insurance Experiment (1995)Cost-Effectiveness in Health and Medicine (1996)Willingness to Pay for a Quality-adjusted Life Year (2000)A community empowerment approach to the HIV response among sex workers: effectiveness, challenges, and considerations for implementation and scale-up (2014)The cost of multiple sclerosis drugs in the US and the pharmaceutical industry (2015)A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)
this work references cited by second hop

References

  • 1996Recommendations of the Panel on Cost-Effectiveness in Health and Medicine2,455 cited
  • 2004A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)615 cited
  • 2008What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?578 cited

Cited by

  • 2019Cost-effectiveness of precision medicine: a scoping review112 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work